Leerink analyst Jonathan Chang raised the firm’s price target on Nanobiotix (NBTX) to $14 from $9 and keeps an Outperform rating on the shares. Nanobiotix reported the first data update for NBTXR3 in anti-PD-1 resistant melanoma from its Phase I Study 1100, showing promising results that are supportive of further investigation in this indication, the analyst tells investors in a research note. Given the early nature of the data, Leerink continues to view this opportunity as upside to the firm’s estimates.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBTX:
- Nanobiotix Reveals Promising Phase 1 Results for Melanoma Treatment
- Nanobiotix announces new results from JNJ-1900 study
- Nanobiotix Updates Voting Rights and Share Capital Information
- Nanobiotix to Present at H.C. Wainwright Investment Conference
- Nanobiotix Announces Voting Rights and Share Capital Update